MXPA05013565A - Proteinas de fusion analogas al glp-1. - Google Patents

Proteinas de fusion analogas al glp-1.

Info

Publication number
MXPA05013565A
MXPA05013565A MXPA05013565A MXPA05013565A MXPA05013565A MX PA05013565 A MXPA05013565 A MX PA05013565A MX PA05013565 A MXPA05013565 A MX PA05013565A MX PA05013565 A MXPA05013565 A MX PA05013565A MX PA05013565 A MXPA05013565 A MX PA05013565A
Authority
MX
Mexico
Prior art keywords
fusion proteins
inhibition
glp
analog
gastric
Prior art date
Application number
MXPA05013565A
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Claesner
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05013565(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA05013565A publication Critical patent/MXPA05013565A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA05013565A 2003-06-12 2004-06-10 Proteinas de fusion analogas al glp-1. MXPA05013565A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47788003P 2003-06-12 2003-06-12
PCT/US2004/015595 WO2005000892A2 (en) 2003-06-12 2004-06-10 Glp-1 analog fusion plroteins

Publications (1)

Publication Number Publication Date
MXPA05013565A true MXPA05013565A (es) 2006-03-09

Family

ID=33551775

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013565A MXPA05013565A (es) 2003-06-12 2004-06-10 Proteinas de fusion analogas al glp-1.

Country Status (28)

Country Link
US (2) US7452966B2 (enExample)
EP (2) EP1641823B1 (enExample)
JP (1) JP4629047B2 (enExample)
KR (1) KR100758755B1 (enExample)
CN (2) CN1802386B (enExample)
AR (1) AR044776A1 (enExample)
AT (1) ATE525395T1 (enExample)
AU (1) AU2004251145C1 (enExample)
BE (1) BE2015C007I2 (enExample)
BR (1) BRPI0411132B8 (enExample)
CA (1) CA2528591C (enExample)
CY (2) CY1111991T1 (enExample)
DK (1) DK1641823T3 (enExample)
EA (1) EA008831B1 (enExample)
ES (1) ES2371072T3 (enExample)
FR (1) FR15C0010I2 (enExample)
HR (1) HRP20110714T1 (enExample)
HU (1) HUS1500024I1 (enExample)
IL (1) IL171926A (enExample)
LT (1) LTC1641823I2 (enExample)
MX (1) MXPA05013565A (enExample)
NZ (1) NZ543292A (enExample)
PL (1) PL1641823T3 (enExample)
PT (1) PT1641823E (enExample)
SI (1) SI1641823T1 (enExample)
TW (1) TW200507870A (enExample)
UA (1) UA87458C2 (enExample)
WO (1) WO2005000892A2 (enExample)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
MXPA04003798A (es) * 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
UA87009C2 (ru) * 2004-12-22 2009-06-10 Эли Лилли Энд Компани Композиции, которые содержат гибридные белки-аналоги glp-1
BRPI0609676A2 (pt) * 2005-05-13 2011-10-18 Lilly Co Eli composto de glp-1 peguilado,e, uso do mesmo
WO2007012188A1 (en) * 2005-07-27 2007-02-01 Qinghua Wang GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
US8278420B2 (en) 2005-08-06 2012-10-02 Qinghua Wang Composition and method for prevention and treatment of type I diabetes
ES2397289T3 (es) * 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
CA2627444A1 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
PT1965823T (pt) * 2005-11-04 2016-08-18 Glaxosmithkline Llc Métodos para administração de agentes hipoglicémicos
CN101534846B (zh) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007124461A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
US7812121B2 (en) * 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
CN103230598A (zh) * 2006-09-06 2013-08-07 费斯生物制药公司 融合肽治疗组合物
WO2008112325A2 (en) * 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP5890085B2 (ja) * 2007-01-05 2016-03-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
DK2109457T3 (en) 2007-02-12 2016-04-11 Csl Behring Gmbh THERAPEUTIC USE OF KAZAL TYPE SERINE PROTEASE INHIBITORS
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
BRPI0813139A8 (pt) * 2007-06-19 2019-01-29 Glytech Inc peptídeo glp-1 com adição de cadeia oligossacarídea
US20110034373A1 (en) * 2007-08-03 2011-02-10 Eli Lilly And Company Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
AU2008318876B2 (en) * 2007-10-30 2014-05-15 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
EP2217701B9 (en) 2007-10-30 2015-02-18 Indiana University Research and Technology Corporation Glucagon antagonists
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
AU2009210570B2 (en) * 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CL2009001425A1 (es) * 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP2307037A4 (en) * 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
AU2009262476C1 (en) 2008-06-24 2016-06-02 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
MX341149B (es) 2008-10-10 2016-08-09 Amgen Inc Mutantes fgf21 y uso de los mismos.
CA2747499A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
LT3248610T (lt) * 2009-05-05 2024-01-25 Amgen Inc. Fgf21 mutantai ir jų panaudojimas
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
EP2443145A1 (en) * 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
JP2013512672A (ja) * 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
KR20130093470A (ko) 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
RU2604067C2 (ru) 2010-05-13 2016-12-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2012010553A1 (en) * 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
CA2824143C (en) 2011-01-14 2018-12-18 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
WO2012120128A1 (en) 2011-03-09 2012-09-13 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
HRP20181690T4 (hr) 2011-03-29 2025-01-03 Roche Glycart Ag Varijante protutijela fc
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
PE20140724A1 (es) 2011-06-22 2014-07-10 Univ Indiana Res & Tech Corp Coagonistas del receptor de glucagon/glp-1
EP4516811A3 (en) 2011-07-22 2025-03-26 CSL Behring GmbH Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
ES2672880T3 (es) 2011-11-17 2018-06-18 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor de glucocorticoides
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
RU2015101697A (ru) 2012-06-21 2016-08-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, обладающие активностью рецептора gip
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
PE20150650A1 (es) * 2012-09-12 2015-05-26 Genzyme Corp Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
JP6026002B2 (ja) 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
MX377150B (es) 2012-11-27 2025-03-07 Biomarin Pharm Inc Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.
CA2901225C (en) 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
IL319584A (en) 2013-03-11 2025-05-01 Genzyme Corp Polypeptides with hyperglycosidic bonds
BR112015023071A2 (pt) 2013-03-14 2017-07-18 Univ Indiana Res & Tech Corp conjugados de insulina-incretina
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
WO2014207199A1 (en) 2013-06-28 2014-12-31 Csl Behring Gmbh Combination therapy using a factor xii inhibitor and a c1-inhibitor
CN103408669B (zh) 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
CN104592381A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种利拉鲁肽中间体多肽的制备方法
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
CN116333148A (zh) 2014-03-19 2023-06-27 建新公司 靶向模块的位点特异性糖工程化
EP3127923B1 (en) * 2014-03-31 2021-08-18 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
CN106659771B (zh) 2014-07-02 2021-09-24 康诺贝林伦瑙有限公司 修饰的von Willebrand因子
DK3172227T3 (da) 2014-07-21 2019-12-02 Delinia Inc Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
CN104293834B (zh) * 2014-10-11 2018-03-23 上海兴迪金生物技术有限公司 GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
WO2016102562A1 (en) 2014-12-23 2016-06-30 Novo Nordisk A/S Fgf21 derivatives and uses thereof
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
TN2017000432A1 (en) 2015-04-10 2019-04-12 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
CN107787328B (zh) 2015-05-22 2021-08-06 康诺贝林伦瑙有限公司 用于治疗血友病的截短的血管性血友病因子多肽
CN107810194B (zh) 2015-05-22 2021-10-08 康诺贝林伦瑙有限公司 用于制备经修饰的血管性血友病因子的方法
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
IL296682B1 (en) 2015-12-23 2025-10-01 Amgen Inc Method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20180132831A (ko) 2016-04-06 2018-12-12 시에스엘 리미티드 죽상동맥경화증의 치료 방법
EP3448885A4 (en) 2016-04-26 2020-01-08 R.P. Scherer Technologies, LLC ANTIBODY CONJUGATES AND METHOD FOR THE PRODUCTION AND USE THEREOF
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
EP3568149B1 (en) 2016-11-10 2025-03-12 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
CA3043397A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
EP3351262A1 (en) 2016-12-30 2018-07-25 Istanbul Universitesi Rektorlugu Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
CN108570109B (zh) 2017-03-14 2022-04-26 广东东阳光药业有限公司 包含免疫球蛋白Fc部分的双靶点融合蛋白
BR112019021923A2 (pt) 2017-04-21 2020-06-02 Yuhan Corporation Método para produzir proteínas de função dupla e suas derivadas
JP7191043B2 (ja) 2017-06-01 2022-12-16 イーライ リリー アンド カンパニー 慢性腎疾患の治療のためのデュラグルチド
KR20200019122A (ko) 2017-06-20 2020-02-21 암젠 인크 Glp-1 작용제와 조합하여 위 저해 펩타이드 수용체(gipr)에 대한 결합 단백질을 이용하여 대사 장애를 치료하거나 또는 개선시키는 방법
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
WO2018234518A1 (en) 2017-06-22 2018-12-27 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
MY207828A (en) 2017-09-22 2025-03-21 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof
MA50798A (fr) 2017-11-21 2020-09-30 Lilly Co Eli Procédés d'utilisation et compositions contenant du dulaglutide
US11752173B2 (en) 2017-12-19 2023-09-12 Beijing Jiyuan Biological Technology Co., Ltd. FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
IL307483A (en) 2017-12-22 2023-12-01 Novartis Ag Methods for treating metabolic disorders with FGF21 variants
US11491235B2 (en) 2017-12-22 2022-11-08 Kb Biomed Inc. Oral gene carrier and use thereof
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN116098989A (zh) 2018-02-08 2023-05-12 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
EP3823659A4 (en) 2018-07-19 2022-06-22 D&D Pharmatech Inc. PHARMACEUTICAL COMPOSITION WITH A POLYPEPTIDE
KR20200135618A (ko) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
CN110878127B (zh) 2018-09-06 2022-06-28 浙江柏拉阿图医药科技有限公司 长效重组GLP1-Fc-CD47蛋白及其制备和用途
MX2021004665A (es) 2018-10-22 2021-08-24 Janssen Pharmaceutica Nv Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas.
WO2020089051A1 (en) 2018-10-29 2020-05-07 F. Hoffmann-La Roche Ag Antibody formulation
CN111234000B (zh) * 2018-11-28 2023-05-26 鲁南制药集团股份有限公司 艾塞纳肽类似物
CN111269312B (zh) * 2018-12-04 2023-05-09 鲁南制药集团股份有限公司 一种异源融合蛋白质
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN111662373B (zh) * 2019-03-05 2024-05-14 广东东阳光药业股份有限公司 一种多肽分子及其应用
MX2021010737A (es) 2019-03-08 2021-09-28 Amgen Inc Terapia de combinacion por factor de diferenciacion del crecimiento 15.
US20220143187A1 (en) * 2019-03-15 2022-05-12 Eli Lilly And Company Preserved formulations
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
JOP20210282A1 (ar) * 2019-04-23 2023-01-30 Lg Chemical Ltd بولي ببتيد اندماج يتضمن منطقة fc لجلوبيولين مناعي وgdf15
BR112021022940A2 (pt) 2019-05-17 2022-01-18 Csl Behring Ag Haptoglobina para uso no tratamento de um resultado neurológico secundário após um acidente vascular cerebral hemorrágico
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
KR20220054689A (ko) 2019-10-15 2022-05-03 일라이 릴리 앤드 캄파니 재조합적으로 조작된, 리파제/에스테라제-결핍 포유동물 세포주
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
EP4200429A1 (en) 2020-08-24 2023-06-28 The Trustees of The University of Pennsylvania Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
CN114106194B (zh) * 2020-08-31 2024-01-16 中国科学院天津工业生物技术研究所 一种用于治疗糖尿病和/或肥胖症的融合蛋白
AU2021381360A1 (en) 2020-11-20 2023-06-22 Csl Behring Gmbh Method for treating antibody-mediated rejection
CN114685644A (zh) 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
AU2022214388A1 (en) 2021-02-01 2023-07-27 Csl Behring Ag Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
US20250304655A1 (en) 2021-05-07 2025-10-02 Csl Behring Ag Expression System for Producing a Recombinant Haptoglobin (Hp) Beta Chain
KR20240029769A (ko) 2021-07-06 2024-03-06 수조우 알파맵 씨오., 엘티디. 융합단백질 및 이의 응용
EP4288461A4 (en) 2021-07-14 2025-07-02 Beijing Ql Biopharmaceutical Co Ltd FUSION POLYPEPTIDES FOR METABOLIC DISORDERS
AR129357A1 (es) 2022-05-18 2024-08-14 Protomer Tech Inc Compuestos aromáticos que contienen boro y análogos de insulina relacionados
CN114774496B (zh) * 2022-06-21 2022-10-04 北京惠之衡生物科技有限公司 一种高密度发酵制备glp-1类似物的方法
CN119789862A (zh) 2022-09-02 2025-04-08 瑞士杰特贝林生物制品有限公司 用于治疗或预防过度勃起反应或勃起功能障碍的触珠蛋白
US20240199728A1 (en) 2022-09-21 2024-06-20 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
EP4593864A1 (en) 2022-09-28 2025-08-06 Zealand Pharma A/S Methods for treating obesity
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024132147A1 (en) 2022-12-22 2024-06-27 Lifearc Galanin-2 receptor agonists
CN120917038A (zh) 2023-03-23 2025-11-07 伊莱利利公司 生产含有Fc的蛋白质的方法
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025122835A2 (en) 2023-12-08 2025-06-12 Eli Lilly And Company Methods of producing fc-containing proteins
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity
WO2025257801A1 (en) 2024-06-13 2025-12-18 CSL Innovation Pty Ltd Heme-binding protein for the treatment of ischemia-reperfusion injury (iri)

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
ES2038579T3 (es) 1989-04-28 1997-02-16 Rhein Biotech Proz & Prod Gmbh Celulas de levadura del genero schwanniomyces.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
ES2279508T3 (es) * 1992-11-13 2007-08-16 Immunex Corporation Ligando elk, una citoquina.
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1932535A3 (en) 1998-07-31 2008-10-29 Novo Nordisk A/S Stimulation of beta cell profileration
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
JP4115671B2 (ja) 1999-05-17 2008-07-09 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期間持続するインシュリン向性ペプチド
EA008837B1 (ru) 2000-06-16 2007-08-31 Эли Лилли Энд Компани Аналоги глюкагоноподобного пептида и их применение
DK1724284T3 (da) * 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusionsproteiner
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP2277888A3 (en) * 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.

Also Published As

Publication number Publication date
KR100758755B1 (ko) 2007-09-14
LTC1641823I2 (lt) 2016-12-12
CY2015002I2 (el) 2017-04-05
TW200507870A (en) 2005-03-01
EA200600015A1 (ru) 2006-06-30
US8273854B2 (en) 2012-09-25
WO2005000892A2 (en) 2005-01-06
IL171926A0 (en) 2006-04-10
HRP20110714T1 (hr) 2011-11-30
BE2015C007I2 (enExample) 2023-08-09
LTPA2015007I1 (lt) 2015-03-25
EP2368909A1 (en) 2011-09-28
CA2528591A1 (en) 2005-01-06
AU2004251145B2 (en) 2010-09-09
ATE525395T1 (de) 2011-10-15
FR15C0010I2 (fr) 2015-07-24
CN101974090B (zh) 2015-06-17
KR20060022262A (ko) 2006-03-09
US7452966B2 (en) 2008-11-18
CN1802386B (zh) 2010-12-15
PT1641823E (pt) 2011-11-08
PL1641823T3 (pl) 2012-02-29
BRPI0411132A (pt) 2006-07-18
FR15C0010I1 (enExample) 2015-03-13
HK1149566A1 (en) 2011-10-07
DK1641823T3 (da) 2011-12-12
ES2371072T3 (es) 2011-12-27
IL171926A (en) 2010-12-30
HUS1500024I1 (hu) 2017-04-28
WO2005000892A3 (en) 2005-03-03
NZ543292A (en) 2008-04-30
JP2007536902A (ja) 2007-12-20
UA87458C2 (ru) 2009-07-27
JP4629047B2 (ja) 2011-02-09
CN101974090A (zh) 2011-02-16
CY2015002I1 (el) 2015-11-04
EP1641823B1 (en) 2011-09-21
EP1641823A2 (en) 2006-04-05
BRPI0411132B1 (pt) 2016-12-13
AU2004251145A1 (en) 2005-01-06
US20090074769A1 (en) 2009-03-19
AR044776A1 (es) 2005-10-05
AU2004251145C1 (en) 2011-04-14
CY1111991T1 (el) 2015-11-04
BRPI0411132B8 (pt) 2021-05-25
EA008831B1 (ru) 2007-08-31
CN1802386A (zh) 2006-07-12
CA2528591C (en) 2013-01-08
SI1641823T1 (sl) 2011-12-30
US20070036806A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
MXPA05013565A (es) Proteinas de fusion analogas al glp-1.
NO20073372L (no) GLP-1-analoge fusjonsproteinformuleringer
NO20076415L (no) GLP-1 pegylerte forbindelser
CY1116917T1 (el) Αναλογα οξυντομοντουλινης
MX2009002999A (es) Analogos de insulina resistentes a proteasa.
JP2010031018A5 (enExample)
JP2009137973A5 (enExample)
NO20054310L (no) Polyetylenglykolbundede GLP-1-forbindelser
CN115920077A (zh) 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物
MY138708A (en) Biaryloxymethylarenecarboxylic acids
WO2008155900A1 (ja) 糖鎖付加glp-1ペプチド
SE0401842D0 (sv) Infusion and injection solution of levodopa
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
NO20076239L (no) Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom
Rothan et al. Antiviral cationic peptides as a strategy for innovation in global health therapeutics for dengue virus: high yield production of the biologically active recombinant plectasin peptide
BRPI0510163A (pt) compostos de amidas tri(ciclo)-substituìdas
DK2186830T3 (da) Polyethylenglycol modificeret interferon alpha 2B og fremstillingsfremgangsmåde og applikationer deraf
CY1106771T1 (el) Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2
BR112021006477A2 (pt) combinação que compreende uma substância com atividade para um receptor de glucagon ou um conjugado do mesmo, kit e composição farmacêutica para prevenir ou tratar doenças
NO20055692L (no) Intravenos injeksjon av ikkeneurotoksiske plasminogenaktivatorer til behandling av cerebralt slag
EP1882474A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR DEVIATIONS IN SUGAR / FATTY CHANGE
AU2019405389B2 (en) Pharmaceutical composition containing insulin and glucagon
UA106506C2 (uk) Інсулінвмісний фармацевтичний препарат для перорального застосування
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
Castilho et al. Heterologous expression, characterization and structural studies of a hydrophobic peptide from the HIV-1 p24 protein

Legal Events

Date Code Title Description
FG Grant or registration